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To the Editor: In their recent assessment of 
Mycobacterium chimaera risk in patients undergo-
ing heart valve surgery, Sommerstein et al. com-
pare their findings to our prior risk assessment for 
UK patients (1,2). In their article, the authors note 
their assessed risk as “4 to 7” times higher than our 
risk estimate and suggest this relates to differences 
in case-finding methodology. Our study reported 
incidence density (cases per 10,000 person-years) 
to account for the differing lengths of postopera-
tive follow-up in each successive annual cohort of 
surgical patients. In contrast, Sommerstein et al. 
calculated crude risk based on annual procedure 
numbers. Since our published assessment was un-
dertaken some years before the authors’ assess-
ment, additional cases have been diagnosed, in 
keeping with the long incubation period for these 
infections, a median of 15 months but up to 5 years 
(3). Recalculation of risk and 95% (binomial) CIs, 
limited to 2008–2014 to match the authors’ assess-
ment, would yield a crude risk estimate of 0.24 
(0.15–0.35) per 1,000 procedures (24/102,234); the 
risk in Switzerland (11/14,054) would be estimated 
at 0.78 (0.39–1.40), just over 3 times higher.
Whether the observed differences between the 
United Kingdom and Switzerland represent a true 
difference in M. chimaera risk in patients undergo-
ing heart valve surgery is subject to debate. Both 
countries based case finding on results from rou-
tine diagnostic investigation; however, awareness 
of the risk in Switzerland predates that in other 
countries, potentially increasing the likelihood of 
investigation for mycobacterial infection. We have 
observed considerable variation in risk between 
cardiac centers, from 0 cases rising to 1 per 100 pa-
tients for 1 center in their year of highest estimated 
risk (4). Our pooled estimate covering 33 centers 
may encompass a wider selection of risk profiles, 
compared with the smaller number of centers in 
Switzerland.
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In Response: We would like to thank Lamagni et 
al. (1) for including additional cases from the period 
of 2008–2014 and for recalculating the UK cumulative 
incidence risk by matching our assessment. We agree 
that the observed 3 times higher risk in Switzerland 
of Mycobacterium chimaera infection for a patient un-
dergoing heart valve surgery cannot be explained un-
ambiguously. The most likely explanation is indeed 
increased awareness of the risk in Switzerland com-
pared with other countries, potentially improving 
likelihood of investigation for mycobacterial infec-
tion. We think that the early formation of a national 
and interdisciplinary working group (M. chimaera 
Task Force), which included representatives of the 
involved (para-)medical disciplines, authorities, and 
professional associations, has contributed greatly to 
raising this awareness.
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